Tums-Maker’s Sales Grow as Weight-Loss Drug Users Grapple With Uncomfortable Side Effects
Haleon, maker of Tums and Advil, reports increased sales of products addressing GLP-1 drug side effects. The company, spun off from GSK in 2022, sees potential in the growing GLP-1 market, with 10% of Americans using these weight-loss drugs. Haleon's shares have fallen 9.3% in 2026, and it aims for 3%-5% full-year revenue growth. The company is partnering with retailers like CVS to boost sales.
How this was made
The 30-second read
Why it matters
Haleon's new retail strategy aims to capture this demand and improve its modest organic growth.
Market read
First report of Haleon's targeted sales initiative, relevant for traders watching consumer health stocks.
What to watch
Potential supply constraints or pricing pressure on OTC products could offset shelf‑placement gains.
Background
GLP‑1 weight‑loss drugs cause gastrointestinal side effects, creating demand for OTC remedies.
Ticker impact
Haleon disclosed new shelf‑placement strategy for Tums and Advil targeting GLP‑1 weight‑loss drug users, expecting a 24% sales lift per store.
Modest upside pressure if sales lift materializes.
The company is seeking incremental growth after a 9.3% share decline; the new strategy may help meet its 3‑5% full‑year target.
Market effects
Consumer health OTC segment could see increased demand from GLP‑1 users, benefiting peers.
U.S. retail pharmacy channels may see higher shelf traffic for antacids and painkillers.
Highlights a secondary growth avenue for consumer health companies worldwide.
Counterpoint
Sales lift may be limited if GLP‑1 users switch to prescription alternatives or if competition intensifies.
Key entities
- CompanyHaleon
British consumer healthcare group, maker of Tums and Advil.
